All In Biotech

Drug Trial Radar · NCT01878617

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

660

Actual

Start

Jun 23, 2013

Primary completion

Oct 13, 2028

Study completion Oct 13, 2031

Sponsor

Lead sponsor
St. Jude Children's Research HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Genentech, Inc.; National Cancer Institute (NCI)
First posted
Jun 17, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years, up to 39 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Historically, medulloblastoma treatment has been determined by the amount of leftover disease present after surgery, also known as clinical risk (standard vs. high risk). Recent studies have shown that medulloblastoma is made up of distinct molecular subgroups which respond differently to treatment. This suggests that clinical risk alone is not adequate to identify actual risk of recurrence. In order to address this, we will stratify medulloblastoma treatment in this phase II clinical trial based on both clinical risk (low, standard, intermediate, or high risk) and molecular subtype (WNT, SHH, or Non-WNT Non-SHH). This stratified clinical and molecular treatment approach will be used to evaluate the following: * To find out if participants with low-risk WNT tumors can be treated with a lower dose of radiation to the brain and spine, and a lower dose of the chemotherapy drug cyclophosphamide while still achieving the same survival rate as past St. Jude studies with fewer side effects. * To find out if adding targeted chemotherapy after standard chemotherapy will benefit participants with SHH positive tumors. * To find out if adding new chemotherapy agents to the standard chemotherapy will improve the outcome for intermediate and high risk Non-WNT Non-SHH tumors. * To define the cure rate for standard risk Non-WNT Non-SHH tumors treated with reduced dose cyclophosphamide and compare this to participants from the past St. Jude study. All participants on this study will have surgery to remove as much of the primary tumor as safely possible, radiation therapy, and chemotherapy. The amount of radiation therapy and type of chemotherapy received will be determined by the participant's treatment stratum. Treatment stratum assignment will be based on the tumor's molecular subgroup assignment and clinical risk. The participant will be assigned to one of three medulloblastoma subgroups determined by analysis of the tumor tissue for tumor biomarkers: * WNT (Strata W): positive for WNT biomarkers * SHH (Strata S): positive for SHH biomarkers * Non-WNT Non-SHH, Failed, or Indeterminate (Strata N): negative for WNT and SHH biomarkers or results are indeterminable Participants will then be assigned to a clinical risk group (low, standard, intermediate, or high) based on assessment of: * How much tumor is left after surgery * If the cancer has spread to other sites outside the brain \[i.e., to the spinal cord or within the fluid surrounding the spinal cord, called cerebrospinal fluid (CSF)\] * The appearance of the tumor cells under the microscope * Whether or not there are chromosomal abnormalities in the tumor, and if present, what type (also called cytogenetics analysis)

Conditions

  • Medulloblastoma

Interventions

  • Craniospinal Irradiation with boost to the primary tumor siteRadiation

    All participants will undergo craniospinal irradiation (CSI) with boost to the primary tumor site. The dose given is based on the molecular and risk group as noted in the arm descriptions. The type of radiation used includes conformal radiation therapy (photons) or intensity modulated radiation therapy (IMRT) or proton beam therapy.

  • CyclophosphamideDrug

    Route of Administration (ROA): Intravenously (IV)

  • CisplatinDrug

    ROA: IV

  • VincristineDrug

    ROA: IV

  • VismodegibDrug

    ROA: Orally (PO)

  • PemetrexedDrug

    ROA: IV

  • GemcitabineDrug

    ROA: IV

  • Aerobic TrainingOther

  • Neurocognitive RemediationOther

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival in Stratum W1Time frame: 2 years after diagnosis
  2. Progression-free Survival in Stratum N1Time frame: 2 years after diagnosis
  3. Progression-free Survival in Stratum S1 Skeletally Mature CohortTime frame: 2 years after diagnosis
  4. Change in VO2 Peak ValueTime frame: baseline and 12 weeks post-randomization
  5. Change in Spatial Span Backward Standard ScoreTime frame: baseline and 10-12 weeks post baseline

Locations

23 sites in 4 countries. Site status is shown where the registry gives one.

  • Lucille Packard Children's Hospital at Stanford University Medical Center

    Palo Alto, California

  • Rady Children's Hospital

    San Diego, California

  • Yale University

    New Haven, Connecticut

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • University of Florida

    Gainesville, Florida

  • Arnold Palmer Hospital for Children

    Orlando, Florida

  • Children's Hospital and Clinics of Minnesota

    Minneapolis, Minnesota

  • Duke Children's Hospital and Health Center

    Durham, North Carolina

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • St. Jude Children's Research Hospital

    Memphis, Tennessee

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • Cook Children's Medical Center

    Fort Worth, Texas

  • Texas Children's Cancer Center

    Houston, Texas

  • Sydney Children's Hospital

    Randwick, New South Wales, Australia

  • Children's Hospital at Westmead

    Westmead, New South Wales, Australia

  • Queensland Children's Hospital

    Brisbane, Queensland, Australia

  • Royal Children's Hospital, Melbourne

    Melbourne, Victoria, Australia

  • Perth Children's Hospital

    Perth, Western Australia, Australia

  • Alberta Children's Hospital

    Calgary, Alberta, Canada

  • The Hospital for Sick Children

    Toronto, Ontario, Canada

  • Centre Hospitalier Universitaire Sainte-Justine

    Montreal, Quebec, Canada

  • Starship Children's Hospital

    Auckland, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.